Skip to main content

Table 1 Literature review of hypofractionated radiotherapy schemes for the treatment of prostate cancer in the postoperative setting

From: Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial

Study (ref.) Design Setting (patient number) Total dose, Gy Dose per fraction, Gy EQD2 (prostate cancera) BED (early toxicitya) BED (late toxicitya)
Tandberg [30] Retrospective Salv. (138)/Adj. (29) 65b 2.5 74.29 81.25 119.17
Kruser [33] Retrospective Salv. (108) 65 2.5 74.29 81.25 119.17
Lewis [31] Retrospective Salv. (43)/Adj. (13) 65b 2.5 71.43 78.13 114.58
Cuccia [32] Retrospective Salv. (38)/Adj. (37) 63.8 2.2 67.45 77.84 110.59
Barra [34] Retrospective Salv. (32)/Adj. (32) 62.5 2.5 71.43 78.13 114.58
Alongi [35] Retrospective Salv. (9)/Adj. (30) 70b 2.5 80 87.5 128.33
Saldi [27] Phase I/II Salv. (72)/Adj. (40) 72–74.25c 2.25 77.14–79.55 88.2–90.96 126–129.94
Katayama [26] Phase I/II Salv. (28)/Adj. (11) 54 3 69.43 70.2 108
Gladwish [29] Phase I/II Salv. (26)/Adj. (4) 51 3 65.57 66.3 102
Macchia [28] Phase I/II Salv. (18)/Adj. (106) 62.5 2.5 71.43 78.13 114.58
This study Phase III Salv. (288) 65 2.5 74.29 81.25 119.17
  1. EQD2 equivalent dose in 2-Gy fractions, BED biologically equivalent dose, Salv. salvage, Adj. adjuvant
  2. aα/β ratio for prostate cancer is 1.5, 10 for early-responding normal tissue, and 3 for late-responding normal tissue
  3. bMedian
  4. cSalvage